Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready
Amylyx Pharmaceuticals, Inc. has 4 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 4 distinct examiners and 3 distinct art units, indicating that examiner assignments are fully distributed while one technical unit includes more than one matter.
BOWLES, DAVID PAUL is the busiest examiner, with 1 pending matter. The profile favors matter-specific prosecution review, with art-unit consistency providing the main available basis for coordinating related work.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (25%) |
| Double-patenting + other | 1 (25%) |
| Multi-statute (no §101) | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BOWLES, DAVID PAUL | 1 | 69.6% | +28.1% |
| VALLE, ERNESTO | 1 | 65.8% | +32.9% |
| MEYERING, SHABANA SHABBEER | 1 | 68.5% | +45.1% |
| BEANE, RANDALL L | 1 | 32.9% | +36.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18314761 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | MEYERING, SHABANA SHABBEER | — |
| 17285039 | AVEXITIDE FOR THE TREATMENT OF HYPERINSULINEMIC HYPOGLYCEMIA | BEANE, RANDALL L | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18372753 | METHODS AND COMPOSITIONS FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS | VALLE, ERNESTO | 34d |
| 19420848 | TREATMENT OF POST-BARIATRIC HYPOGLYCEMIA | BOWLES, DAVID PAUL | — |
| 18314761 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | MEYERING, SHABANA SHABBEER | — |
| 17285039 | AVEXITIDE FOR THE TREATMENT OF HYPERINSULINEMIC HYPOGLYCEMIA | BEANE, RANDALL L | — |
| Art Unit | Apps |
|---|---|
| 1654 | 2 |
| 1623 | 1 |
| 1635 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19420848 | TREATMENT OF POST-BARIATRIC HYPOGLYCEMIA | BOWLES, DAVID PAUL | 1654 | §103DP | Final Rejection | — | Pending | Dec 16, 2025 |
| 18372753 | METHODS AND COMPOSITIONS FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS | VALLE, ERNESTO | 1623 | §103Other | Non-Final OA | 34d | Pending | Sep 26, 2023 |
| 18314761 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | MEYERING, SHABANA SHABBEER | 1635 | §102§103§112 | Final Rejection | — | Pending | May 09, 2023 |
| 17285039 | AVEXITIDE FOR THE TREATMENT OF HYPERINSULINEMIC HYPOGLYCEMIA | BEANE, RANDALL L | 1654 | §103§112Other | Non-Final OA | — | Pending | Apr 13, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAmylyx Pharmaceuticals, Inc. has 4 pending office actions as of October 2026, spread across 3 art units and 4 examiners.
David Paul Bowles has the most, with 1 of Amylyx Pharmaceuticals, Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
